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Summary: The urinary ratio of 6 β-hydroxycortisol/cortisol (6 β-OHC/C) as a biomarker of CYP3A4 metabolizing activ-
ity has been studied in Egyptian patients with chronic liver cirrhosis associated with previous hepatic Schistosomiasis infec-
tion to determine any possible alteration in enzyme activity. The ratio of 6-β OHC/C was determined in morning urine 
samples collected from 8:00 a.m. to 12:00 p.m. in healthy adults (n = 36) and patients with liver cirrhosis (n = 57). The 
median age for control was 27 years (range: 18–50 years) and 50 years (range: 27–75 years) for patients. 6 β-OHC was 
detected in urine by ELIZA kits (Stabiligen, France). Patients with liver cirrhosis were categorized according to Child Pugh 
Classiﬁ  cation into Child B (n = 28) and Child C (n = 29) classes. Cholestasis was observed in 9/28 of Child B class and 
8/29 of Child C class of patients. The control subjects showed gender-related difference in the urinary ratio of 6 β-OHC/C. 
A signiﬁ  cant reduction (P < 0.001) in 6 β-OHC/C ratio was observed only in Child C patients in comparison with control 
subjects. Regression analysis showed a signiﬁ  cant correlation (P < 0.05) between 6 β-OHC/C ratio and serum albumin. The 
inﬂ  uence of cholestasis on the urinary ratio of 6-β OHC/C was observed on cirrhotic patients of Child B class. In conclu-
sion, patients with chronic liver cirrhosis might have a reduction of metabolizing activity of CYP3A4 enzymes which could 
be identiﬁ  ed by measuring the urinary ratio of 6 β-OHC/C. This reduction is more apparent in severe liver injury (Child C 
class). Therefore, it is important to understand the metabolic fate of drugs metabolized by 3A4 enzymes in patients with 
liver cirrhosis to avoid drug accumulation that might lead to development of drug toxicity.
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Introduction
Cytochrome P450 enzymes (CYP450) are heme-containing monooxygenases responsible for the 
metabolism of numerous xenobiotics including therapeutic drugs, environmental chemicals, dietary 
constituents and endogenous substrates such as steroids and bile acids. They activate metabolic 
transformation of these compounds into water soluble and less toxic substances that are easily 
eliminated from the body (Eichelbaum and Burk, 2001; Furuta et al. 2003). However, these enzymes 
may also transform nontoxic chemicals into reactive intermediates that are likely toxic or carcinogenic 
(Rendic S and DiCarlo, 1997).
CYP3A is the most highly expressed subfamily of cytochrome P450 isozymes in humans and it 
includes the isoforms 3A4, 3A5, 3A7 and 3A43 (Shimada et al. 1994). The CYP3A subfamily plays an 
important role in the biotransformation of more than 50% of drugs in clinical use such as macrolide 
antibiotics, benzodiazepines, calcium channel blockers, immunosuppressive drugs and chemotherapeutic 
agents (Thummel and Wilkinson, 1998). CYP3A4 is the most abundant isoform expressed in liver and 
intestine with high inter-individual variability in its protein level and catalytic activity (Guengerich, 
1992; Ozdemir, 2000).
Several noninvasive in vivo probes for estimating the inter-patient variability of CYP3A4 activity have 
been reported and include the erythromycin breath test, the urinary dapsone recovery test, measurement 
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of midazolam clearance (CL), and measurement 
of the ratio of endogenous urinary 6-beta-hydroxy-
cortisol to free-cortisol (Hunt et al. 1992; Watkins 
et al. 1992; Kinirons et al. 1993; Thummel et al. 
1994). Of all the probes tried, midazolam plasma 
clearance and the erythromycin breath test have 
been the most rigorously studied and appear to be 
the most reliable methods (Streetman et al. 2000; 
Goh et al. 2002).
Estimation of urinary ratio of 6 β-hydroxycor-
tisol/cortisol (6 β-OHC/C) has been suggested as 
a simple non-invasive biochemical marker to 
determine the activity of CYP3A4 in human 
(Wilkinson, 1996; Galteau and Shamsa, 2003). 
Although the ratio does not always correlate with 
the disposition of CYP3A substrate drugs, 
including the typical phenotyping probe drugs 
such as [
14C]-erythromycin and midazolam (Hunt 
et al. 1992; Watkins et al. 1992; Kinirons et al. 
1993, 1999), but recent studies have described 
successful utilization of the urinary ratio
6 β-OHC/C as a measure of CYP3A induction 
(Saima et al. 2002; Uejima et al. 2002; ELDesoky 
et al. 2005; Yeo et al. 2006). Furthermore, the 
urinary ratio has also been studied in some disease 
conditions to elucidate a possible correlation of 
CYP3A activity with disease states such as 
hepatic disease, thyroid disorders and cancer (NG 
et al. 1996; Zheng et al. 2001; Szucs et al. 2003; 
Kishino et al. 2004; Hoshiro et al. 2006).
Liver cirrhosis due to chronic hepatitis B or 
hepatitis C viral infection is a common medical 
problem in Egypt. In many cases especially for 
hepatitis C (HCV) infected patients living in rural 
areas, it is accompanied by Schistosomal hepatic 
ﬁ  brosis due to previous Schistosomal parasitic 
infestation (Angelico et al. 1997). This combined 
viral and parasitic liver infection exhibits a unique 
clinical, virological, and histopathological pattern 
where the infective virus persists with high HCV 
RNA titers, the necroinﬂ  ammatory and ﬁ  brosis 
scores in liver biopsies become higher and response 
to interferon therapy is poor (Pereira, 1995; 
Kamal et al. 2000). With progression of liver 
cirrhosis, both liver function and hepatic blood 
ﬂ  ow are impaired. So, the metabolizing capacity 
of liver microsomal enzymes including CYP3A 
has been expected to reduce (Shiffman et al. 1995; 
Bastein et al. 2000). 
In the present study, we have estimated the 
urinary ratio of 6 β-hydroxycortisol/cortisol in spot 
urine samples of Egyptian patients with chronic 
liver cirrhosis due to hepatitis B or hepatitis C viral 
infection associated with previous schistosomal 
infection. The urinary ratio of 6 β-hydroxycortisol/
cortisol was used as a simple non-invasive 
biomarker to assess CYP3A4 activity in these 
hepatic patients in comparison with Egyptian 
control subjects. The inﬂ  uence of cholestasis if 
present in association with the hepatic disease 
conditions on the ratio was also investigated. 
Furthermore, a possible correlation between the 
urinary ratio of 6 β-OHC/C and different biochem-
ical parameters of liver function (e.g. serum 
albumin and transaminases) in cirrhotic liver was 
also studied.
Material and Methods
Patient and control subjects
Fifty seven patients with post-hepatitis liver 
cirrhosis due to hepatitis B or hepatitis C viral 
infection associated with past history of Shisto-
somal infection were selected for the study. 
Patients attended the Tropical Medicine and 
Gastroenterology Department, Assiut University 
Hospital, Assiut, Egypt for medical care. The 
diagnosis of liver cirrhosis was based on clinical 
manifestations of liver cell failure (e.g. ascites 
and jaundice), biochemical ﬁ  ndings (e.g. hypoal-
buminemia, hyperbilirubinemia, abnormal 
coagulation proﬁ  le and elevation of liver enzymes) 
and ultrasonography. Endoscopy was carried out 
if needed. Serological tests for hepatitis B virus 
antigen (HBsAg) and hepatitis C virus antibodies 
(HCVAb) conﬁ  rmed the previous viral hepatitis 
infection of the liver. The serological tests for 
hepatitis markers were done using Abbott 
AXSYM System. The method of assay is based 
on micro particle enzyme immunoassay (MEIA). 
Inclusion or not of cholestasis in association with 
liver cirrhosis was based on Clinical ﬁ  ndings such 
as itching, jaundiced skin or sclera, deep dark 
urine and clay colored or white stool. Laboratory 
diagnosis of cholestasis included elevation of 
serum levels of both bilirubin and alkaline phos-
phatse enzyme [ALP] in parallel with elevation 
of serum gamma glutamyl transferase [GGT] 
enzyme. Also, abdominal ultrasonography and 
CT scan imaging studies helped to conﬁ  rm the 
intrahepatic obstructive lesions that caused 
cholestasis.
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Diagnosis of previous Schistosomal infection 
relied upon endemicity of Schistosomal infection 
in rural areas where selected patients were living, 
past history of Schistosomal infection and exposure 
of the patients to anti bilharzial drug therapy, and 
rectal biopsy. Abdominal sonography including the 
liver (for the presence of Schistosomal hepatic 
periportal ﬁ  brosis) was applied to conﬁ  rm previous 
Schistosomal affection of the liver. No patient had 
clinically active Schistosomiasis. Patients had no 
history of alcohol intake but 15 of them were ciga-
rette smokers. No drugs known to affect the activity 
of CYP3A4 were given to the patients (e.g. macro-
lide antibiotics, contraceptives, or antifungal 
agents of an azole structure). Table 1 demonstrates 
the demographic and relevant clinical data of 
selected patients. 
Thirty six healthy subjects (26 males & 10 
females) were included in the study as a control 
group with median age of 27 (range: 18–50 years). 
They were non-smokers and have no history of 
previous chronic illness and laboratory ﬁ  ndings 
especially liver and kidney function tests were 
within normal. Also, they had negative history of 
receiving drugs known to affect CYP3A4 activity 
for at least two months before running of the 
study.
Liver function tests were done for all subjects 
(patients & control) in the Clinical Pathology 
laboratories at Assiut University Hospital, Assiut, 
Egypt. They included determination of serum 
albumin, bilirubin, alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), and 
alkaline phosphatase. Also, serum creatinine and 
prothrombin time were estimated.
Urine samples collection
In the morning of the day of the study, urine 
samples were collected as spot urine in the period 
from 08:00 a.m. to 12:00 a.m. Then, samples for 
Table 1. Characteristics of cirrhotic patients included in the study.
 Total  Reference  values*
N  57 (Child B: 28)**
       (Child C: 29)**
Age
1 (years)  50 (45–60)
Gender (F/M)  8/49
Smoking
2 16/57
Ascites
2 29/57
Serum albumin
1 (g/l)  23 (19.9–28.6)  25.4–36.2
Total serum bilirubin
1 (umol/l)  44 (24.5–100)  11.0–17.0
Serum ALT
1 (U/L)  56 (40–70)  29.0–41.0
Serum AST
1 (U/L)  83 (60–130)  37.7–54.5
Serum ALP
1 (U/L):    135–195
   no cholestasis (n = 40)  117 (82.5–170) 
   with cholestasis (n = 17)  301 (238–467)
GGT
1 (U/L):    5–85
   no cholestasis (n = 40)  50.9 (23–86.9)
   with cholestasis (n = 17)  879.9 (698.7–1087)
Prothrombin time
1 (seconds)  18.8 (16–20)  11.0–15.0
Serum creatinine
1 (umol/l)  109 (70–190)  80.4–115.8
CLcr 
1,a (ml/min)  85 (60–105)  80–140
HBs Ag positive
2 15/57  (26%)
HCV Ab positive
2 42/57  (74%)
HBs Ag positive & HCV Ab positive
2 46/57  (80%)   
ALT: alanine transferase, AST: aspartate transferase, ALP: alkaline phosphatase, GGT: gama glutamyl transpferase,
CLcr: creatinine clearance.
* As followed up in the laboratory. ** Child-Pugh classiﬁ  cation
1 Data represent the median values with the 25th and 75th percentiles in parenthesis.
2 Data represent the number of patients in this category relative to the total number of patients. 
a Estimated according to Cockroft equation 
(Cockcroft et al. 1976).
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Table 2. Urinary ratio of 6β-OHC/C (ng/ml) in healthy 
control subjects.
Control subjects  Urinary ratio of 6β-OHC/C
 Median
Total:    (n  =  36)  10.4
Male:      (n = 26)  14.7
a
Female:  (n = 10)   3.6
a Mann-Whitney U-test (versus female; p < 0.01)
each patient were divided into portions and kept 
frozen at –20°C without adding any preservatives 
till the time of assay.
Assay methods
(i) Assay of urinary 6 β-hydroxycortisol 
(6 β-OHC) Urinary concentrations of 6β-OHC were 
assayed using enzyme-linked immunoassay kits 
(ELISA technique) which were given as a gift from 
Stabiligen (54603, Villers-Les-Nancy-France). The 
mechanism of measurement by the kits was based 
on a competitive immune reaction where the 
competitive ligands in the kits were 6 β-hydroxy-
cortisol conjugated to horseradish peroxidase and 
penicillinase enzymes respectively (Zhiri et al. 
1986). The minimum detection limit (sensitivity) of 
6β-OHC by Stabiligen kits was 50 pg/ml. The intra-
assay precisions were 4% (C.V %) at a mean 
concentration of 697 pg/ml and 10% at a 69.9 pg/ml 
respectively. The inter-assay variations were 3% at 
a mean concentration of 731 pg/ml and 7.2% at a 
mean concentration of 72.1 pg/ml.
(ii) Assay of free cortisol in urine Free cortisol 
was assayed in urine using DSL-2100 Active
© 
Cortisol coated-tube radio immunoassay kits 
(Diagnostic Systems Laboratories, Inc, Webster, 
Texas 77598-4217, U.S.A). The sensitivity of the 
assay was 0.3 µg/dl. The intra-assay precisions 
were 8.4% (C.V %) at a mean concentration of 5.0 
µg/dl and 5.3% at 19.2 µg/dl respectively. The 
inter-assay variations were 9.1% at a mean concen-
tration of 4.83 µg/dl and 8.9% at 19.18 µg/dl 
respectively.
Statistical Analysis
The ratio of 6β-OHC/C was expressed as median 
values and non-parametric tests e.g. Mann-Whitney 
U test was used for comparison. Regression 
analysis and analysis of variance (ANOVA) were 
used to assess a possible correlation between 
urinary ratio of 6β-OHC/C and any of the demo-
graphic factors (e.g. age, gender, and smoking) or 
biochemical parameters (e.g. serum creatinine, 
albumin, bilirubin, alkaline phosphatase, etc) 
measured in cirrhotic patients. Statistical signiﬁ  -
cance was considered at p < 0.05.
Results
The inﬂ  uence of urine concentration on the urinary 
ratio of 6β-OHC/C in control subjects was assessed 
by studying the correlation between levels of 
urinary creatinine and corresponding ratio of 6β-
OHC/C in urine samples. No signiﬁ  cant relation 
was observed.
Assessment of urinary ratio of 6β-OHC/C in 
control subjects showed wide range (1-73 ng/ml) 
with signiﬁ  cantly higher median values in males 
compared with female controls (Table 2). 
Table 3 demonstrated the influence of liver 
cirrhosis on the values of urinary ratio of 6β-OHC/C. 
Child C but not Child B cirrhotic patients had a 
signiﬁ  cant reduction (p < 0.001) in the urinary ratio 
of 6β-OHC/C compared with control subjects. 
Also, Child C patients had signiﬁ  cantly lowered 
urinary values of 6β-OHC/C in comparison with 
Child B cirrhotic patients.
Table 4 showed a trend (but not signiﬁ  cant) 
for urinary ratio of 6β-OHC/C in patients with 
Child B class of liver cirrhosis to elevate in the 
presence of cholestasis compared with control 
subjects. On the other hand, Child B patients with 
no cholestasis had a signiﬁ  cant lowering of the 
ratio of 6β-OHC/C compared with control group. 
Regarding Child C class of patients, it seemed 
that the severe liver cell injury in this class of 
patients irrespective of the presence or absence 
of cholestasis was significantly affecting the 
urinary ratio of 6β-OHC/C in comparison with 
Child B and/or control subjects. 
Non-parametric correlation analysis revealed 
no significant influence of smoking, age, or 
creatinine clearance on the urinary ratio of 6β-
OHC/C in patients with hepatic cirrhosis. Study 
of the relation between urinary ratio of 6β-OHC/
C and different biochemical parameters of liver 
function demonstrated a signiﬁ  cant correlation 
between the ratio and serum albumin (r = 0.4, 
p < 0.05) (Fig.1). On the other hand, both ALT 
and prothrombin time showed a trend to negative 
but not signiﬁ  cant correlation with the urinary 
ratio of 6β-OHC/C.
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Discussion
The present study showed gender-related differ-
ence in the activity of CYP3A4 among Egyptians 
(Table 2). Among the control group, females had 
lower values of the urinary ratio of 6β-OHC/C in 
comparison with males; a result that coincides with 
previously reported data among Egyptians 
(ELDesoky et al. 2005) and other populations (Lee, 
1995; NG et al. 1996). However, other studies 
demonstrated higher values of the urinary ratio in 
females compared with males (Inagaki et al. 2002). 
Although lack of gender inﬂ  uence on the activity 
of the enzyme was also reported (McCune et al. 
2001), some studies reported differences in the 
urinary ratio of 6β-OHC/C in the same sex but of 
different ethnicity (Lin et al. 1999). Therefore, the 
inﬂ  uence of gender on the activity of CYP3A4 is 
still an unresolved observation.
The wide range of the urinary ratio of 6β-OHC/C 
(1.0–73.0 ng/ml) in the control group is in agree-
ment with other studies (Chen et al. 2004; Yin et al. 
2004) which all reﬂ  ect a wide interindividual vari-
ability in the urinary excretion of 6β-hydroxycor-
tisol in different populations. Among the Egyptian 
controls studied, gender seems to play a role in this 
variability between males and females. However, 
the genetic component is likely to contribute 
signiﬁ  cantly in the variability (Yin et al. 2004). 
Therefore, an expected variability in CYP3A4 gene 
expression among different populations should be 
considered (Hustert et al. 2001; Koch et al. 2002; 
Lin et al. 2002). 
Child C class of patients where more deteriora-
tion of liver function was expected showed signif-
icant reduction in the urinary ratio of 6β-OHC/C 
in comparison with control subjects and Child B 
class of patients (Table 3). These results reﬂ  ected 
possible reduction in the activity of CYP3A4 in 
patients with chronic liver cirrhosis to form 6 
β-hydroxycortisol metabolite and the more the 
liver injury, the more the reducing effect on 
CYP3A4 activity. A previous study demonstrated 
similar reduction in the urinary ratio of 6β-OHC/C 
among patients with liver cirrhosis in comparison 
with control subjects (Shibuya et al. 2003). Another 
study which investigated the activity and protein 
content of CYP3A4 in cirrhotic liver tissue 
revealed a signiﬁ  cant reduction in both parameters 
of the enzyme in comparison with healthy liver 
(Yang et al. 2003). Also, the anatomical and patho-
physiological changes associated with hepatic 
cirrhosis might contribute in the reduction of 
Table 3. Urinary ratio of 6β-OHC/C (ng/ml) in cirrhotic patients compared with healthy 
control subjects.
Group  Urinary ratio of 6β-OHC/C (ng/ml)
 Median  p-value#
Control subjects (n = 36)  10.4
Cirrhotic patients (n = 57):
Child B (n = 28; ♀: n = 3)  7.8 
a <0.05
Child C (n = 28; ♀: n = 5)  1.3 
b <0.001
a versus Child C, 
b versus control. 
# Mann-Whitney U- test.
Table 4. Urinary ratio of 6β-OHC/C (ng/ml) in cirrhotic patients with and without cholestasis in comparison with 
healthy control subjects.
6β-OHC/C  Control  Child B cirrhosis  Child C cirrhosis
(ng/ml)  subjects  Choles  No Choles  Choles  No Choles
  (n = 36)  (n = 9)  (n = 19)  (n = 8)  (n = 21)
Median value  10.4  17*  6
a,# 0.5
b 1.9
c
Choles = cholestasis. No Choles = no cholestasis.
Mann-Whitney U-test was used for statistical analysis.
Versus control: 
aP < 0.05, 
bP < 0.01, 
cP < 0.001
Versus Child C with cholestasis: *P < 0.001
Versus Child C without cholestasis: 
#P < 0.05
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CYP3A4 metabolizing activity (Shibuya et al. 
2003; Horiike et al. 2005). All these ﬁ  ndings might 
explain the reduced clearance of highly extracted 
drugs like lidocaine in patients with liver cirrhosis 
so that the given dose of the drug has to be reduced 
(Orlando et al. 2003). 
A signiﬁ  cant reduction in the urinary ratio of 
6β-OHC/C was observed in Child B cirrhotic patients 
who had no cholestasis while it showed a tendency 
to increase (but not signiﬁ  cant) in cholestatic Child 
B patients in comparison with control subjects 
(Table 4). These ﬁ  ndings reﬂ  ect a selective inﬂ  uence 
of the cholestasis on the urinary ratio of 6β-OHC/C 
in Child B cirrhotic patients especially this group 
collectively and without stratiﬁ  cation according to 
concomitant cholestasis showed no signiﬁ  cant differ-
ence in the ratio in comparison with the control group 
(Table 3). It has been suggested that P450 3A 
hydroxyls activity and 3A protein are reduced in 
patients with liver cirrhosis without cholestasis 
(George et al. 1995). Elevation of the urinary ratio 
of 6β-OHC/C in the presence of cholestasis may 
have many reasons at molecular levels of CYP3A 
proteins. Bile acid or drug-induced cholestasis may 
lead to activation of pregnane X receptor (PXR) 
which induces human cytochrome P4503A4 to cata-
lyze 6-hydroxylation of bile acids for renal excretion 
(Gnerre et al. 2004; Li and Chiang, 2005; Li and 
Chiang, 2006). Furthermore, CYP3A4 may be adap-
tively up-regulated in cholestasis with unknown 
mechanism. It is suggested that CYP3A4 can metab-
olize lithocholic acid into 3-dehydrolithocholic acid, 
a potent activator of the nuclear receptors, pregnane 
X receptor and 1,25-dihydroxy vitamin D3 receptor, 
which are known to regulate the expression of 
CYP3A4 (Bodin et al. 2005). 
On the other hand, stratification of Child C 
cirrhotic patients according to cholestasis did not 
affect the signiﬁ  cantly lowered values of urinary 
ratio of 6β-OHC/C in comparison with either control 
subjects or Child B cirrhotic patients (Table 4). 
Therefore, it seems that the severe injury of liver 
cell in Child C patients is more inﬂ  uential than other 
concomitant pathological ﬁ  ndings in the liver such 
as cholestasis on the ratio of 6β-OHC/C.
In patients with liver cirrhosis, hypoalbumin-
emia is a common biochemical ﬁ  nding (Table 1) 
which represents a reduction in the synthetic power 
of cirrhotic liver to produce albumin. This might 
explain the positive correlation between serum 
albumin and urinary values of 6β-OHC/C in 
patients with liver cirrhosis (ﬁ  g.1). The impaired 
expression of hepatic proteins including CYP3A4 
might affect the metabolism of endogenous cortisol 
into its metabolite; 6 β-hydroxycortisol (Shibuya 
et al. 2003; Horiike et al. 2005). Also, the concen-
tration of albumin in blood is thought to affect the 
disposition or biotransformation of drugs by regu-
lating their penetration into liver (Ludden et al. 
1997). Therefore, hypoalbuminemia in patients 
with liver cirrhosis may result in alteration in the 
proposed protein-facilitated metabolism of drugs 
and endogenous substances (e.g. cholesterol & sex 
steroids) which are metabolized by CYP3A4 (Baba 
et al. 2002). The observed negative correlation (but 
not signiﬁ  cant) between the urinary values of
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Figure 1. Relation between urinary 6 beta OHC/C ratio and serum albumin in cirrhotic patients (r = 0.4,P < 0.05).
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6 β-OHC/C and both ALT and prothrombin time 
in our results reﬂ  ected a trend of CYP3A4 activity 
to reduce in liver cirrhosis. 
In conclusion, patients with chronic liver 
cirrhosis might have a reduction of metabolizing 
activity of CYP3A4 enzymes which could be 
identified by measuring the urinary ratio of
6 β-OHC/C. This reduction is more apparent in 
severe liver injury. Liver cirrhosis associated with 
cholestasis is likely to modify the activity of 
CYP3A4.
A prospective study is suggested on a large 
number of Egyptian healthy controls and patients 
with liver cirrhosis to study the correlation between 
CYP3A4 mRNA titer in blood and the urinary ratio 
of 6 β-hydroxycortisol/cortisol in a trial to explain 
the wide variability in CYP3A4 activity among 
Egyptians.
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